FI97692B - Förfarande för framställning av ett terapeutiskt användbart konjugat av en aktivator och en målsökande del - Google Patents

Förfarande för framställning av ett terapeutiskt användbart konjugat av en aktivator och en målsökande del Download PDF

Info

Publication number
FI97692B
FI97692B FI913511A FI913511A FI97692B FI 97692 B FI97692 B FI 97692B FI 913511 A FI913511 A FI 913511A FI 913511 A FI913511 A FI 913511A FI 97692 B FI97692 B FI 97692B
Authority
FI
Finland
Prior art keywords
antibody
activator
lysozyme
prodrug
targeting moiety
Prior art date
Application number
FI913511A
Other languages
English (en)
Finnish (fi)
Other versions
FI913511A0 (sv
FI97692C (sv
Inventor
Nicholas Pomato
Reinhard Bredehorst
Chong-Ho Kim
Richard Mccabe
Carl-Wilhelm Vogel
Original Assignee
Akzo Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23161497&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FI97692(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nv filed Critical Akzo Nv
Publication of FI913511A0 publication Critical patent/FI913511A0/sv
Publication of FI97692B publication Critical patent/FI97692B/sv
Application granted granted Critical
Publication of FI97692C publication Critical patent/FI97692C/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899—Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nanotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)

Claims (10)

1. Förfarande för framställning av ett terapeutiskt användbart konjugat av en aktivator och en mälsökande del 5 innehällande lysozym som aktivator och en human monoklonal antikropp eller ett fragment därav som mälsökande del, kännetecknat därav, att man kopplar nämnda aktivator tili nämnda mälsökande del med en kovalent bind-ning pä sä sätt att konjugatet bibehäller förmägan att 10 binda antigen och att aktivera ett proläkemedel som inne-häller en spjälkbar molekyl.
2. Förfarande för framställning av ett terapeutiskt användbart proläkemedel innehällande ett antikancermedel som innehäller en spjälkbar molekyl som förhindrar upp- 15 tagning i cellen, kännetecknat därav, att man konjugerar nämnda spjälkbara molekyl med ett antikancermedel .
3. Förfarande enligt patentkrav 2, kännetecknat därav, att antikancermedlet derivatiserats 20 med en chitinoligomermellangrupp.
4. Förfarande enligt patentkrav 3, kännetecknat därav, att antikandermedlet är ett antra-cyklin.
5. Förfarande enligt patentkrav 4, k ä n n e - 25 tecknat därav, att chitinoligomermellangruppen är fäst via en aminogrupp vid ett ställe, vilket valts bland C13-karbonylstället i antracyklinet och sockerdelen av antracyklinet.
6. Förfarande enligt patentkrav 5, k ä n n e - 30 tecknad därav, att chitinoligomerderivatet inne-häller (GlcNAc)n, väri n är 1 - 10, bär negativt laddade grupper och en reaktiv grupp, vilken tilläter kovalent bindning vid antracyklinet.
7. Förfarande enligt patentkrav 7, k ä n n e - 35 tecknat därav, att de negativt laddade grupperna är sulfonater, fosfater, karboxylater eller fosfonater. ii m i un i i t.M . 97692 37
8. Förfarande enligt patentkrav 6, känne- t e c k n a t därav, att antalet negativt laddade grup-per är 1 - 10.
9. Förfarande enligt patentkrav 3, känne- 5 tecknat därav, att chitinoligomermellangruppen är bunden kovalent vid läkemedlet via en aktiv grupp, vilken valts bland disulfid-, tloester-, imld-, halogen-, amin-, karboxyl-, ester-, tiol- och alkoholgrupper.
10. Förfarande enligt patentkrav 6, känne-10 tecknat därav, att den reaktiva gruppen väljs bland disulfid-, tioester-, imid-, halogen-, amin-, karboxyl-, ester-, tiol- och alkoholgrupper.
FI913511A 1989-01-23 1991-07-22 Förfarande för framställning av ett terapeutiskt användbart konjugat av en aktivator och en målsökande del FI97692C (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US30099989A 1989-01-23 1989-01-23
US30099989 1989-01-23
PCT/US1990/000503 WO1990007929A1 (en) 1989-01-23 1990-01-23 Site specific in-vivo activation of therapeutic drugs
US9000503 1990-01-23

Publications (3)

Publication Number Publication Date
FI913511A0 FI913511A0 (sv) 1991-07-22
FI97692B true FI97692B (sv) 1996-10-31
FI97692C FI97692C (sv) 1997-02-10

Family

ID=23161497

Family Applications (1)

Application Number Title Priority Date Filing Date
FI913511A FI97692C (sv) 1989-01-23 1991-07-22 Förfarande för framställning av ett terapeutiskt användbart konjugat av en aktivator och en målsökande del

Country Status (12)

Country Link
EP (1) EP0454783B1 (sv)
JP (1) JP3273608B2 (sv)
KR (1) KR0185967B1 (sv)
AT (1) ATE123414T1 (sv)
AU (1) AU648015B2 (sv)
CA (1) CA2025899A1 (sv)
DE (1) DE69019959T2 (sv)
DK (1) DK0454783T3 (sv)
ES (1) ES2075893T3 (sv)
FI (1) FI97692C (sv)
NO (1) NO912864L (sv)
WO (1) WO1990007929A1 (sv)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5773435A (en) * 1987-08-04 1998-06-30 Bristol-Myers Squibb Company Prodrugs for β-lactamase and uses thereof
US5851527A (en) * 1988-04-18 1998-12-22 Immunomedics, Inc. Method for antibody targeting of therapeutic agents
ATE233100T1 (de) * 1989-08-02 2003-03-15 Mitra Medical Technology Ab System zur verwendung in einem verfahren zur therapeutischen und diagnostischen behandlung
DE4106389A1 (de) * 1991-02-28 1992-09-03 Behringwerke Ag Fusionsproteine zur prodrug-aktivierung, ihre herstellung und verwendung
US6610299B1 (en) 1989-10-19 2003-08-26 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
US7241595B2 (en) 1989-10-20 2007-07-10 Sanofi-Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
US6475486B1 (en) 1990-10-18 2002-11-05 Aventis Pharma Deutschland Gmbh Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
AU649952B2 (en) * 1989-12-11 1994-06-09 Immunomedics Inc. Method for antibody targeting of diagnostic or therapeutic agents
SE9100142L (sv) * 1991-01-17 1992-07-18 Bengt Sandberg En metod och ett system foer foerbaettrad in vivo reducering av diagnostiska och/eller terapeutiska substanser medelst extrakorporeal borttagning, och anvaendandet av naemnda substanser foer detta aendamaal
FR2676058B1 (fr) * 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
AU4663493A (en) * 1992-07-06 1994-01-31 Hybritech Incorporated Method for delivery of cytotoxic agents and components thereof
GB9323429D0 (en) * 1993-11-12 1994-01-05 Wellcome Found Therapy
DE69527805T2 (de) * 1994-12-23 2003-04-24 Astrazeneca Ab, Soedertaelje Chemische mittel
AU707689B2 (en) 1995-08-16 1999-07-15 Astrazeneca Ab Mutated Carboxypeptidase B enzyme conjugated to a tumour targeted antibody for use in Antibody Directed Enzyme Prodrug Therapy
EP0795334B1 (de) * 1996-03-12 2006-02-01 Sanofi-Aventis Deutschland GmbH Neuartige Prodrugs für die Therapie von Tumoren und entzündlichen Erkrankungen
PL229108B1 (pl) * 2014-08-22 2018-06-29 Celther Polska Spolka Z Ograniczona Odpowiedzialnoscia Sposób wydzielania i oczyszczania estrów chityny (mono-, di‑podstawionych) oraz kopoliestrów chityny z mieszanin poreakcyjnych
EP3970752A1 (en) * 2020-09-17 2022-03-23 Merck Patent GmbH Molecules with solubility tag and related methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4067774A (en) * 1971-05-14 1978-01-10 Syva Company Compounds for enzyme amplification assay
US4631190A (en) 1981-06-26 1986-12-23 Shen Wei C Acidity-sensitive spacer molecule to control the release of pharmaceuticals from molecular carriers
LU85581A1 (fr) * 1984-10-10 1986-06-11 Smb Lab Ensembles d'anticorps monoclonaux diriges contre la lactoferrine humaine et le lysozyme humain
JPS62138496A (ja) * 1985-12-11 1987-06-22 Ihara Chem Ind Co Ltd キチンオリゴマ−の製造方法
EP0328578B1 (en) * 1987-07-02 1996-05-08 Akzo Nobel N.V. Antigen recognized by mca 16-88
NZ225599A (en) * 1987-08-04 1991-09-25 Bristol Myers Co Antibody-enzyme conjugates and combinations with prodrugs for the treatment of tumour cells
ZA893284B (en) * 1988-05-04 1990-03-28 Igen Inc Peptide analogs and their use as haptens to elicit catalytic antibodies

Also Published As

Publication number Publication date
DE69019959T2 (de) 1995-10-05
JP3273608B2 (ja) 2002-04-08
ES2075893T3 (es) 1995-10-16
FI913511A0 (sv) 1991-07-22
EP0454783B1 (en) 1995-06-07
WO1990007929A1 (en) 1990-07-26
KR910700072A (ko) 1991-03-13
AU648015B2 (en) 1994-04-14
JPH04503068A (ja) 1992-06-04
DK0454783T3 (da) 1995-10-16
KR0185967B1 (ko) 1999-05-01
EP0454783A4 (en) 1992-01-15
NO912864L (no) 1991-09-19
ATE123414T1 (de) 1995-06-15
NO912864D0 (no) 1991-07-22
DE69019959D1 (de) 1995-07-13
EP0454783A1 (en) 1991-11-06
FI97692C (sv) 1997-02-10
CA2025899A1 (en) 1990-07-24
AU5039790A (en) 1990-08-13

Similar Documents

Publication Publication Date Title
US5433955A (en) Site specific in vivo activation of therapeutic drugs
FI97692C (sv) Förfarande för framställning av ett terapeutiskt användbart konjugat av en aktivator och en målsökande del
AU646121B2 (en) Acid-labile linker molecules
US4937183A (en) Method for the preparation of antibody-fragment conjugates
US5157104A (en) Trichothecene conjugates
AU614532B2 (en) Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells
US5094848A (en) Cleavable diphosphate and amidated diphosphate linkers
EP0294294A2 (en) Amine derivatives of anthracycline antibiotics
JPH03503898A (ja) 薬剤輸送系に関する更なる改良
US5478576A (en) Arabinogalactan derivatives and uses thereof
US5010176A (en) Antibody-drug conjugates
EP0646018A1 (en) Arabinogalactan derivatives and uses thereof
Hurwitz et al. Daunomycin-immunoglobulin conjugates, uptake and activity in vitro
WO1993025225A1 (en) Liposomal formulations for administering to cancer patients
WO1993025225A9 (en) Liposomal formulations for administering to cancer patients
KR930003333B1 (ko) 탄수화물 단위가 변형된 리보솜을 비활성화시키는 당단백질 성분을 함유하는 지속-작용성 면역독소의 제조방법
KR950007215B1 (ko) 오시딕 단위를 산화시키고 쉬프염기를 형성하여 리보솜을 비활성화시키는 당단백질을 변형시키는 방법
CA2114629C (en) Receptor conjugates for targeting antibiotics to bacteria
JPS62175500A (ja) 修飾糖タンパク質、当該修飾糖タンパク質の製造方法、当該修飾糖タンパク質を含む免疫毒素および当該免疫毒素を有効成分として含む抗ガン剤組成物
EP0213881A2 (en) The use of amphipathic molecules for radioimaging and therapy with conjugates of monoclonal or polyclonal antibodies
JPS6069034A (ja) 免疫毒素、免疫毒素を含有する薬剤及び免疫毒素の生体外使用方法
Wilchek Affinity Therapy

Legal Events

Date Code Title Description
BB Publication of examined application